about
Primary antiphospholipid syndrome in Latin American mestizo patients: clinical and immunologic characteristics and comparison with European patients.Pregnancy and catastrophic antiphospholipid syndrome.REAL-PANLAR Project for the Implementation and Accreditation of Centers of Excellence in Rheumatoid Arthritis Throughout Latin America: A Consensus Position Paper From REAL-PANLAR Group on Improvement of Rheumatoid Arthritis Care in Latin America EsTreatment of Raynaud's phenomenon.Use of rituximab in patients with systemic lupus erythematosus: an update.Infections and the antiphospholipid syndrome.Management of patients with rheumatoid arthritis in Latin America: a consensus position paper from Pan-American League of Associations of Rheumatology and Grupo Latino Americano De Estudio De Artritis Reumatoide.Obstetric antiphospholipid syndrome.Current therapies in rheumatoid arthritis: a Latin American perspective.Diagnosis and classification of rheumatoid arthritis.Rheumatoid arthritis in minorities.The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus.Should Rituximab be Considered as the First-Choice Treatment for Severe Autoimmune Rheumatic Diseases?I latin american congress of autoimmunity galapagos--September 15-18Mesenterial thrombosis with the antiphospholipid syndromeThe HELLP syndrome, antiphospholipid antibodies, and syndromes
P50
Q33378048-F200C060-2A26-455B-9812-B9B90571F9FEQ33382266-F659AC31-17E7-4897-AE79-9781288D237CQ35670645-9C74A75B-2603-4522-B04E-61CE499208E0Q37240405-7E7E2459-48D2-4C03-AC20-FDB696FAFE9CQ37335599-2496C199-09B8-4BE1-80C2-6F816ABA4F97Q37352874-A000CD35-C6AB-42E9-BB4E-5C4861172888Q37510479-82128D0D-CB54-439A-84A6-B300EC075947Q37946086-29E31B29-0C1A-474C-A7D8-7C5EECE8CB9EQ38075662-7E3C0DEC-4189-498F-9E90-1B2FEA6C46D5Q38191064-F8B39C2F-ACA9-47F1-92DF-6DA96F5C85DDQ41137156-86B0DDE2-2597-4920-897B-39F88121EB62Q41935106-712FF159-FB17-4556-87CD-D9B8FEE98DA6Q56452729-2EACB0EA-FC9F-44D4-B77C-390BC8D52E34Q75827764-18B560B8-4F85-4F50-8DE9-B1860B61A8AEQ79530924-C8FADB68-D076-43F5-BD56-90D774A39CE2Q81388536-45D7FCCC-2874-4D4C-A1DD-508827AC6B11
P50
description
forsker
@nb
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Claudio Galarza-Maldonado
@ast
Claudio Galarza-Maldonado
@da
Claudio Galarza-Maldonado
@de
Claudio Galarza-Maldonado
@en
Claudio Galarza-Maldonado
@es
Claudio Galarza-Maldonado
@fr
Claudio Galarza-Maldonado
@nb
Claudio Galarza-Maldonado
@nl
Claudio Galarza-Maldonado
@nn
Claudio Galarza-Maldonado
@sv
type
label
Claudio Galarza-Maldonado
@ast
Claudio Galarza-Maldonado
@da
Claudio Galarza-Maldonado
@de
Claudio Galarza-Maldonado
@en
Claudio Galarza-Maldonado
@es
Claudio Galarza-Maldonado
@fr
Claudio Galarza-Maldonado
@nb
Claudio Galarza-Maldonado
@nl
Claudio Galarza-Maldonado
@nn
Claudio Galarza-Maldonado
@sv
prefLabel
Claudio Galarza-Maldonado
@ast
Claudio Galarza-Maldonado
@da
Claudio Galarza-Maldonado
@de
Claudio Galarza-Maldonado
@en
Claudio Galarza-Maldonado
@es
Claudio Galarza-Maldonado
@fr
Claudio Galarza-Maldonado
@nb
Claudio Galarza-Maldonado
@nl
Claudio Galarza-Maldonado
@nn
Claudio Galarza-Maldonado
@sv
P106
P21
P31
P496
0000-0003-4529-6063